Your browser doesn't support javascript.
loading
Paroxysmal nocturnal hemoglobinuria: a red clot syndrome.
Crawford, Jeffrey D; Wong, Victor W; Deloughery, Thomas G; Mitchell, Erica L; Liem, Timothy K; Landry, Gregory J; Azarbal, Amir F; Moneta, Gregory L.
Afiliação
  • Crawford JD; Division of Vascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
  • Wong VW; Division of Vascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
  • Deloughery TG; Division of Hematology and Oncology, the Department of Internal Medicine, Oregon Health and Science University, Portland, OR.
  • Mitchell EL; Division of Vascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
  • Liem TK; Division of Vascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
  • Landry GJ; Division of Vascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
  • Azarbal AF; Division of Vascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR.
  • Moneta GL; Division of Vascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR. Electronic address: monetag@ohsu.edu.
Ann Vasc Surg ; 28(1): 122.e5-10, 2014 Jan.
Article em En | MEDLINE | ID: mdl-24200143
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, nonmalignant disorder of hematopoietic stem cells characterized by hemolysis, diminished hematopoiesis, and thrombophilia. We describe a 65-year-old woman with known PNH and peripheral arterial disease who presented with critical limb ischemia and a nonhealing left foot ulcer. She underwent surgical bypass of a diffusely diseased left superficial femoral artery with autologous reversed saphenous vein graft. Her postoperative course was complicated by wound sepsis and PNH exacerbation with resultant graft thrombosis requiring an above-knee amputation. This case highlights several key concepts relevant to the management of vascular surgery patients with PNH: (1) their predisposition for arterial and venous thrombosis; (2) hypercoagulability despite standard anticoagulation regimens; (3) the role of eculizumab (a monoclonal antibody that inhibits complement activation used to treat PNH) in reducing thrombotic complications and hemolysis; and (4) complications associated with the immunosuppressive effects of eculizumab. We recommend careful monitoring of hemolysis and immunosuppression, aggressive anticoagulation, frequent graft surveillance, and early consultation with hematology.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Veia Safena / Artéria Femoral / Doença Arterial Periférica / Enxerto Vascular / Hemoglobinúria Paroxística Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Veia Safena / Artéria Femoral / Doença Arterial Periférica / Enxerto Vascular / Hemoglobinúria Paroxística Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article